Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation

NCT03190733 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT03190733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03190733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation
Lead sponsor
Zhujiang Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
August 30, 2017
Completion date
September 30, 2021
Enrollment
192 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host-disease, leukemia relapse